Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF)
Status:
Suspended
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
This is a global, multicenter, open-label, repeat-dose, Phase 1/2 study consisting of a Dose
Escalation Phase (Phase 1) and a Cohort Expansion Phase (Phase 2). In both phases, KB004 will
be administered by IV infusion once weekly as part of a 21-day dosing cycle.